Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
      • Factors associated with young adults opting out of donation for HCT may provide insights into donor availability
      • Alternative donor HCT may yield comparable outcomes and expand access for myelofibrosis patients
      • Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
      • Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • Myelodysplastic Syndromes (MDS)
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Myeloproliferative Neoplasms
Research Spotlight
  • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL

    September 2019

  • New Prognostic System for Patients with Relapsed Follicular Lymphoma

    May 2018

  • Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT

    May 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Hodgkin Lymphoma
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Subscribe to the Latest Research
  • All Outcomes and Trends Data

Patient Resources

  • Transplant Outcomes and Treatment Decisions
  • Transplant and Hodgkin Lymphoma (PDF)
  • Transplant Basics Booklet
  • Transplant Basics Videos

Hodgkin Lymphoma

Approximately 8,500 individuals are diagnosed with Hodgkin lymphoma (HL) each year in the United States. HL is most frequently diagnosed among people aged 20-34 years. [1] Hematopoietic cell transplantation (HCT), often autologous but occasionally allogeneic, is a treatment option for recurrent disease. Allogeneic HCT outcomes in patients with relapsed/refractory HL have significantly improved over time. [2,3] 

Outcomes  

Data in this section have been prepared by the CIBMTR® (Center for International Blood and Marrow Transplant Research). The CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin. 

Figure 1. HL Survival, Autologous and Allogeneic HCT  

Figure 1. HL Survival, Autologous and Allogeneic HCT

Download slide

Figure 2. Survival Trends Over Time, HL HCT  

Figure 2. Survival Trends Over Time, HL HCT

Download slide

HCT Consultation Timing Guidelines  

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Transplantation and Cellular Therapy (ASTCT) have jointly developed guidelines for transplant consultation and referral timing based on disease characteristics. [4] The National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines®) were consulted when developing these guidelines and are a valuable tool in determining risk stratification. [2] 

Our guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [4]

Transplant Consultation Guidelines: Hodgkin Lymphoma 

  • Primary induction failure 
  • First relapse 
  • CR2 or subsequent relapse 

Download as a slide 

View complete  HCT Consultation Timing Guidelines

Clinical Trials Search and Support  

The NMDP/Be The Match offers the Be The Match® Jason Carter Clinical Trials Search and Support (CTSS) program, which can provide clinical trial navigation to your patients. The CTSS Program was created to help people with blood cancers or blood disorders and their families find and join clinical trials.

For more information, visit Clinical Trials Search and Support.  

References 

  1. SEER Stat Fact Sheets: Hodgkin Lymphoma. Website accessed 2 November, 2017. Access
  2. National Comprehensive Cancer Network. Hodgkin Lymphoma. (Version 2.2023). Access
  3. Hegerova L, Cao Q, Lazaryan A, et al. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017; 52(5): 697-703. Access
  4. NMDP/Be The Match and ASTCT Recommended Timing for Transplant Consultation. Download (PDF) 
    • Email
    • Print This Page

    Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

    Transplant Indications and Outcomes

    • HLA Today
    • Disease-Specific Indications and Outcomes
    • Additional Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members

    Transplant Therapy and Donor Matching

    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
    • Jason Carter Clinical Trials Program

    Resources

    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program

    Contact Us

    National Marrow Donor Program —
    Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
    Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright